Silk Road Medical, Inc (2OW.SG)
| Previous close | 15.60 |
| Open | 16.10 |
| Bid | 16.10 x N/A |
| Ask | 16.50 x N/A |
| Day's range | 15.40 - 16.10 |
| 52-week range | 5.80 - 39.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 666.967M |
| Beta (5Y monthly) | 1.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference
SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference. Management is scheduled to present on Tuesday, May 14, 2024, at 3:40 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: ht
- GlobeNewswire
Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online using t
- GlobeNewswire
Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio. This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep expe
